REG - Solvonis Therapeutic - Solvonis secures exclusive CNS collaboration

Solvonis TherapeuticsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250828:nRSb9220Wa&default-theme=true

RNS Number : 9220W  Solvonis Therapeutics PLC  28 August 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

28 August 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Solvonis secures exclusive CNS collaboration with CSO Professor David Nutt, establishes Scientific Advisory Committee and Issue of Equity

 

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders,
is delighted to announce amendments to its consultancy agreement with
Professor David Nutt, the Company's Chief Scientific Officer. Under the
revised terms, Professor Nutt will increase his commitment to Solvonis, serve
as Interim Chair of the newly established Scientific Advisory Committee
("SAC"), and work exclusively with the Company in the field of commercial drug
discovery and development for CNS disorders.

Professor Nutt is one of the world's foremost authorities in
neuropsychopharmacology, with more than 600 peer-reviewed publications and a
career spanning over four decades. He holds the Edmond J. Safra Chair in
Neuropsychopharmacology at Imperial College London, has chaired the UK
Advisory Council on the Misuse of Drugs, and has served as President of the
European College of Neuropsychopharmacology, the British Neuroscience
Association, and the British Association of Psychopharmacology. His pioneering
research has advanced both the scientific understanding and clinical treatment
of a wide range of brain disorders.

The amendments to the agreement mark three important developments for
Solvonis:

·      Expanded commitment - Professor Nutt's role increases to two days
per week (40% FTE).

·      Exclusive collaboration - his commercial CNS drug discovery and
development expertise will be applied solely to Solvonis' programmes.

·      Strengthened governance - as Interim Chair of the SAC, Professor
Nutt will convene leading international experts to provide independent
oversight and recommendations directly to the Board.

Anthony Tennyson, CEO of Solvonis, commented: "Professor David Nutt's
leadership has already been central to shaping Solvonis' pipeline. By securing
his exclusive collaboration in CNS drug discovery and development, and
establishing our Scientific Advisory Committee under his chairmanship, we are
embedding world-class expertise into both our science and our governance. This
strengthens Solvonis' position as a company uniquely focused on translating
cutting-edge neuroscience into innovative therapies for CNS disorders."

Professor David Nutt, CSO of Solvonis, added: "I am delighted to deepen my
commitment to Solvonis at such an exciting stage in its growth. By focusing my
commercial CNS drug development work exclusively with Solvonis and chairing
the new Scientific Advisory Committee, I look forward to helping shape the
Company's scientific strategy and ensuring our programmes are guided by the
highest standards of innovation and rigour. Solvonis has the potential to make
a real impact across the CNS field, and I am proud to be part of that
mission."

Issue of Equity in Lieu of Fees

The Company has also agreed with certain creditors to settle outstanding
liabilities relating to services historically delivered to the Company
amounting to £286,681 through the issue of 141,875,231 new ordinary shares of
£0.0001 each. This comprises: (i) 81,732,308 shares at an issue price of
£0.0013 and 60,142,923 shares at an issue price of £0.003. Application will
be made for the new ordinary shares to be admitted to trading on the Main
Market of the London Stock Exchange, with Admission expected to occur on or
around 3(rd) September. The new shares will rank pari passu in all respects
with the existing ordinary shares. Following Admission, the Company's issued
share capital will comprise 6,403,979,255 ordinary shares, each carrying one
voting right.

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds targeting high-burden neuropsychiatric conditions with
significant unmet need.

The Company's lead programmes address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD), conditions affecting over 80 million
people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in
Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase
2b trial in the US targeting moderate to severe AUD. Solvonis also has a
preclinical PTSD programme leveraging novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery platform built on
a proprietary CNS compound library, with initial focus on depression and
stimulant use disorders. This initiative expands the Company's R&D
pipeline into earlier-stage innovation while maintaining strategic focus on
comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

solvonis.com (https://solvonis.com) | LinkedIn
(https://www.linkedin.com/company/solvonis) | X (Twitter)
(https://x.com/Solvonis)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFLFFSTIIDFIE